| (210) | Number of the EPO application | 17794505 |
| (220) | Filing date of the EPO application | 2017.10.19 |
| (80) | EPO patent specification publication (B) | EPB nr. 06/2024, 2024.02.07 |
| (110) | EPO patent number | 3529236 |
| (21) | Number of the application | e 2019 0951 |
| (71) | Name(s) of applicant(s), code of the country | Tetraphase Pharmaceuticals, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | LAFRANCE Danny, US;
HOGAN Philip C., US;
LIU Yansheng, US;
HE Minsheng, US;
CHEN Chi-Li, US;
NIU John, US; |
| (73) | Name(s) of owner(s), code of the country | Tetraphase Pharmaceuticals, Inc., US; |
| (54) | Title of the invention | CRYSTALLINE FORMS OF ERAVACYCLINE |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 295/15 (2006.01.01); A61P 1/00 (2006.01.01); A61P 35/00 (2006.01.01); A61P 31/00 (2006.01.01); A61K 31/65 (2006.01.01); A61P 1/02 (2006.01.01); A61P 31/04 (2006.01.01); A61P 43/00 (2006.01.01); A61P 13/02 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.09.30 |
| (30) | Priority | 201662410230 P, 2016.10.19, US |
| (86) | International application | PCT/US2017/057385, 2017.10.19 |
| (87) | International publication | WO 2018/075767, 2018.04.26 |